MedDataX Logo

Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401

NCT ID: NCT03593499

Last Updated: 2025-05-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NO_LONGER_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an expanded access program for eligible participants and is designed to provide access to omaveloxolone for the treatment of unresectable or metastatic melanoma to patients who previously participated in the 408-C-1401 (REVEAL) study. To be considered for expanded access, a Principal Investigator from the REVEAL trial should submit a request to Reata Pharmaceuticals on behalf of the individual patient.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma

NCT06590480

Advanced Melanoma
NO_LONGER_AVAILABLE

Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

NCT05398640

Unresectable Melanoma Metastatic Melanoma
AVAILABLE

RTA 408 Capsules in Patients With Melanoma - REVEAL

NCT02259231

Melanoma Unresectable (Stage III) Melanoma Metastatic (Stage IV) Melanoma
COMPLETED PHASE1/PHASE2

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

NCT06940739

Ocular Melanoma Unresectable Melanoma Metastatic Melanoma
RECRUITING PHASE1/PHASE2

Treatment Use Study for Advanced Melanoma.

NCT00584493

Advanced Unresectable Melanoma
NO_LONGER_AVAILABLE

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Sponsor, originally Reata Pharmaceuticals, Inc., is now Reata Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melanoma

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

omaveloxolone

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RTA 408

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

Exclusion Criteria

\-
Eligible Sex

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biogen

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

408-C-1401EA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma
NCT00521053 COMPLETED PHASE2
Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma
NCT03084640 COMPLETED PHASE1
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
NCT02147951 NO_LONGER_AVAILABLE
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
NCT00109005 COMPLETED PHASE2
Expanded Access Program With Nivolumab to Treat Melanoma
NCT02142218 NO_LONGER_AVAILABLE
Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1
NCT07040436 NOT_YET_RECRUITING PHASE1/PHASE2
An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas
NCT05928962 UNKNOWN PHASE1
Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma
NCT02297529 NO_LONGER_AVAILABLE
RAD001 Plus Bevacizumab in Metastatic Melanoma
NCT00591734 COMPLETED PHASE2
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
NCT01909453 COMPLETED PHASE3
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
NCT01320085 COMPLETED PHASE2
Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma
NCT03190824 UNKNOWN PHASE2
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
NCT02094872 COMPLETED PHASE2
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
NCT05625399 ACTIVE_NOT_RECRUITING PHASE3
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
NCT07223411 RECRUITING
Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases
NCT05903937 NOT_YET_RECRUITING PHASE1
Intralesional PV-10 Chemoablation of Metastatic Melanoma
NCT00219843 COMPLETED PHASE1
Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention
NCT03817125 COMPLETED PHASE1
Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma
NCT01864759 COMPLETED PHASE1
Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy
NCT02680184 COMPLETED PHASE1
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
NCT00057616 COMPLETED PHASE3
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
NCT05655312 RECRUITING PHASE1/PHASE2
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
NCT05912244 ACTIVE_NOT_RECRUITING PHASE2
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
NCT02908672 COMPLETED PHASE3
Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions
NCT00091689 COMPLETED PHASE1